Loading…
Lobbying Spend
—
Filings
46
Firms Hired
1
Active Period
2006–2018
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
CREATES Act of 2016
2016 · fourth_quarter · Firm: LUSSIER, GREGOR, VIENNA & ASSOCIATES
1. Support The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S.3056). The bill would provide a clear solution to abusive, anti-competitive business practices that increase costs to the American health care system by impeding patient access to generic medicines. 2. Support the Centers for Medicare & Medicaid Services (CMS) Part B Drug Payment Model. 3. General support for a legislative response to projected increases in Medicare Part B premiums and the Part B deductible in 2017.
Client expense: — · Firm income: —
Matched citations: S.3056
CREATES Act of 2016
2016 · third_quarter · Firm: LUSSIER, GREGOR, VIENNA & ASSOCIATES
1. Support The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S.3056). The bill would provide a clear solution to abusive, anti-competitive business practices that increase costs to the American health care system by impeding patient access to generic medicines. 2. Support the Centers for Medicare & Medicaid Services (CMS) Part B Drug Payment Model. 3. General support for a legislative response to projected increases in Medicare Part B premiums and the Part B deductible in 2017.
Client expense: — · Firm income: —
Matched citations: S.3056
CREATES Act of 2016
2016 · second_quarter · Firm: LUSSIER, GREGOR, VIENNA & ASSOCIATES
1. Support The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S.3056). The bill would provide a clear solution to abusive, anti-competitive business practices that increase costs to the American health care system by impeding patient access to generic medicines. 2. Support the Centers for Medicare & Medicaid Services (CMS) Part B Drug Payment Model.
Client expense: — · Firm income: —
Matched citations: S.3056
FAST Generics Act of 2015
2015 · fourth_quarter · Firm: LUSSIER, GREGOR, VIENNA & ASSOCIATES
1. Strongly believe that biologics and biosimilars should be required to have the same International Nonproprietary Name(INN). Oppose the FDAs most recent proposal to add a suffix to traditional INNs. 2. General support for generic drugs (i.e. Hatch-Waxman) and support for enhanced access to biogeneric and biosimilar drugs. Opposition to increases in exclusivity for brand manufacturers that would have the effect of burdening consumers, large and small businesses,and state and federal governments with unnecessary increased prescription drug costs through delayed generic and biosimilar entry. 3. Support the Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2841). 4. General support for the work being done by the bipartisan Senate working group on chronic care.
Client expense: — · Firm income: $5,000
Matched citations: H.R. 2841
Source: Senate LDA